Peptomyc S.L. benefits from the expertise of a strong Development Advisory Board (DAB) comprising the following internationally renowned thought leaders in oncology:
Dr. Thibault is an expert in oncology drug development. He has led clinical programs of chemotherapy, molecularly targeted therapy and biologics in solid tumors and haematological malignancies from the translational and entry-into-man stages to IPO, both in the EU and the US. He was most recently focused on immuno-oncology development targeting co-stimulatory receptors and modification of the tumor micro-environment. His regulatory experience ranges from IND/IMPD-CTA to drug approvals in oncology and rare diseases. Dr. Thibault received his Medical Oncology certification from the National Cancer Institute, USA and his Medicine Doctorate from McGill University, Canada.
Dr. Alfredo Covelli was trained as a medical oncologist at the Department of Neoplastic Disease, Mount Sinai Hospital, New York. Before joining the pharma industry, he held academy positions at Institute of Medical Pathology, School of Medicine, University “Federico I” in Naples, and at the Division of Hematology, School of Medicine, University “La Sapienza” in Rome. Over the last 30 years, he held a variety of Global and Country Management positions in the pharma industry, both in Clinical Research and in Commercial Operations in Italy, France, Switzerland and the US (Farmitalia, Pierre Fabre, Sandoz, and Aventis). In his last position, he served as Vice President and Head, Clinical Research and Medical Affairs, Region Europe, Novartis Oncology. He is now a consultant to various Biotech Companies in developing innovative therapies in oncology.
Dr. Bonnefoy is an expert in R&D of immune-related diseases. Regarding oncology, he has led preclinical and clinical R&D programs with NCEs, antibodies, vaccines, oncolytic viruses and ADCs. He co-founded the first Canceropole in France. He worked for Schering-Plough, GSK, Pierre Fabre, Transgene. He is a coach and chairman of the cancer network Matwin. He co-founded and chaired several start-ups including currently Syndivia and Salto Therapeutics, working on ADCs for solid tumors and pediatric oncology, respectively. Dr. Bonnefoy received his PhD in Immunology from Claude Bernard University in Lyons, France.